4Bio Partners
4Bio Partners, which trades as 4BIO Capital, is a London-headquartered venture capital firm that invests exclusively in the advanced-therapies sector. It backs early-stage life-science companies developing cell and gene therapies, RNA-based therapies, targeted therapies, radiopharmaceuticals and microbiome treatments addressing areas of high unmet medical and social need. The wider 4BIO Capital business has invested since 2014, while the UK management entity, 4BIO Partners LLP, was incorporated in October 2018. The firm has invested in more than 25 advanced-therapies companies, with notable outcomes including the public listings of UniQure and Autolus and the trade sales of Orchard Therapeutics and Araris Biotech. It is authorised and regulated by the UK Financial Conduct Authority under firm reference number 842764. Its latest flagship fund, 4BIO Ventures III, is a 2022-vintage vehicle targeting up to USD 200 million.
Key facts
Recent exits
Coverage notes
2 funds tracked, 15 portfolio companies (12 active · 3 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund 4Bio Partners has raised, with its portfolio companies. Hand-checked from public filings.
4BIO Ventures IIILife Sciences VC2022 · 4yr€184M12 active · 1 realized
Unrealized
12 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Switzerland | 2025 | |
| Biotech |  UK | 2023 | |
| Biotech |  US | 2022 | |
| Biotech | UK | 2026 | |
| Biotech | US | 2022 | |
| Biotech | UK | 2024 | |
| Biotech | Japan | 2022 | |
| Biotech | US | 2024 | |
| Biotech | US | 2021 | |
| Biotech |  France | 2020 | |
| Biotech | UK | 2023 | |
| Biotech | UK | 2023 |
Switzerland· Entry 2025UK· Entry 2023US· Entry 2022UK· Entry 2026US· Entry 2022UK· Entry 2024US· Entry 2024US· Entry 2021France· Entry 2020UK· Entry 2023UK· Entry 2023Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | UK | 2017 | 2018 | IPO | – | – |
4BIO Ventures IILife Sciences VCRealising2019 · 7yr€45M0 active · 2 realized
Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | Switzerland | 2020 | 2025 | Trade Sale | – | ||
| Biotech | US | 2020 | 2022 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
About 4Bio Partners
4BIO Partners (4BIO Capital) is one of the few venture capital firms investing exclusively in advanced therapies with approximately $300 million plus of assets under management as of December 2024 across Ventures II and Ventures III (Ventures III is 2023 vintage, with the Development Bank of Japan joining Ventures III in January 2024), headquartered in London. The firm was founded in 2015 as a specialist VC focused on advanced therapies and operates as 4BIO Partners LLP, FCA-regulated.
Investment thesis
4BIO Partners deploys capital through approximately three funds (4BIO Ventures I, II, III), targeting early-stage venture capital exclusively in advanced therapeutics addressing high unmet medical need. Sector focus spans cell and gene therapy, RNA-based therapeutics, targeted therapies, microbiome and broader advanced and emerging biotech modalities. Geographic deployment is global across the US, UK and Europe, London-based. The platform aims to take advanced therapy modalities (cell, gene, RNA) mainstream.
Recent activity
Recent realised exits include an antibody-drug conjugate and biotech acquisition (2024). Recent investments include oncology viral immunotherapy Series A (2025), gene therapy Series A (2024-2025) and radiopharmaceutical and targeted therapy Series A (2024-2025). The platform continues active deployment of Ventures III across the advanced therapeutics mandate. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
United Kingdom·€309.0B
United Kingdom·€15.4B
United Kingdom·€12.7B
United Kingdom·€11.7B
United Kingdom·€6.4B
United Kingdom·€4.1B
United Kingdom·€3.5B
United Kingdom·€2.3B
United Kingdom·€2.3B
United Kingdom·€1.8B
United Kingdom·€1.8B
United Kingdom·€1.6BGet the full picture on 4Bio Partners.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in